Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Moderna Inc (NASDAQ: MRNA) was $106.18 for the day, down -2.45% from the previous closing price of $108.85. In other words, the price has decreased by -$2.45 from its previous closing price. On the day, 2.78 million shares were traded. MRNA stock price reached its highest trading level at $108.17 during the session, while it also had its lowest trading level at $103.52.
Ratios:
Our analysis of MRNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.36 and its Current Ratio is at 3.42. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, HSBC Securities on February 26, 2024, Downgraded its rating to Reduce and sets its target price to $86 from $75 previously.
On January 02, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $142.
On November 29, 2023, Canaccord Genuity started tracking the stock assigning a Hold rating and target price of $82.Canaccord Genuity initiated its Hold rating on November 29, 2023, with a $82 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 17 ’24 when AFEYAN NOUBAR sold 15,000 shares for $103.38 per share. The transaction valued at 1,550,703 led to the insider holds 2,056,931 shares of the business.
Hoge Stephen sold 15,000 shares of MRNA for $1,575,300 on Apr 15 ’24. The President now owns 1,486,241 shares after completing the transaction at $105.02 per share. On Apr 10 ’24, another insider, AFEYAN NOUBAR, who serves as the Director of the company, sold 15,000 shares for $107.12 each. As a result, the insider received 1,606,865 and left with 2,071,931 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 41676394496 and an Enterprise Value of 33207533568. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.94 while its Price-to-Book (P/B) ratio in mrq is 2.93. Its current Enterprise Value per Revenue stands at 4.849 whereas that against EBITDA is -9.178.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $142.79, while it has fallen to a 52-week low of $62.55. The 50-Day Moving Average of the stock is 4.74%, while the 200-Day Moving Average is calculated to be 7.49%.
Shares Statistics:
MRNA traded an average of 3.76M shares per day over the past three months and 2507210 shares per day over the past ten days. A total of 382.00M shares are outstanding, with a floating share count of 336.37M. Insiders hold about 12.15% of the company’s shares, while institutions hold 67.86% stake in the company. Shares short for MRNA as of 1713139200 were 20981181 with a Short Ratio of 5.58, compared to 1710460800 on 22227123. Therefore, it implies a Short% of Shares Outstanding of 20981181 and a Short% of Float of 7.22.
